Compass Pathways PLC (CMPS)
AI stock analysis · as of Jul 9, 2026
Loading microstructure…
COMPASS Pathways is a UK-based clinical-stage biotech developing COMP360, a synthetic psilocybin therapy for treatment-resistant depression (TRD) with expansion into PTSD and anorexia. Both Phase 3 TRD trials (COMP005/COMP006) hit primary endpoints with p<0.001, and a rolling NDA submission is targeted for Q4 2026 with potential FDA approval in H1 2027. The core investment question: does the derisked pivotal data and ~4M-patient TRD opportunity justify the ~$1.9B market cap despite zero revenue, ongoing ~$160M annual cash burn, single-asset concentration, and DEA scheduling uncertainty for a Schedule I compound?
valuationExpensive on traditional metrics (P/B 5.77, negative EV/EBITDA, zero revenue) but that's typical for pivotal-stage biotech; valuation is really a risk-adjusted NPV of COMP360 — reasonable if you underwrite approval and a multi-hundred-million-dollar peak sales trajectory, rich if launch execution or scheduling disappoints.
This analysis is from Jul 9, 2026. Want the latest on CMPS, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Both Phase 3 TRD trials succeeded on primary endpoint with p<0.001 and MADRS reductions of -3.6/-3.8 points, substantially derisking the regulatory path — rare for a novel mechanism biotech at this stage
- · TAM is meaningful: ~4M U.S. TRD patients with only two FDA-approved therapies (esketamine, olanzapine/fluoxetine); PTSD expansion adds a ~13M patient opportunity where no new drug has been approved in 25+ years
- · Regulatory tailwinds: FDA Breakthrough Therapy designation, accepted rolling NDA pathway, and a supportive policy backdrop from the current administration's stated psychedelic therapy push
- · Sell-side is constructive: 15 analysts, 'strong buy' consensus, mean target $23.60 (~69% upside vs. $13.97), with Evercore ISI upgrade after data; 1 upgrade vs. 0 downgrades in past 90 days
- · 26-week durability readout from COMP006 due early Q3 2026 could differentiate COMP360 versus ketamine/esketamine on retreatment economics and support payer reimbursement
- · Stock trades at $13.97 vs. 52-week high $15.40 but well off $3.45 low — momentum is with the story as pivotal catalysts approach
Bear case
- · Pre-revenue with widening losses: net loss expanded from -$118M (2023) to -$155M (2024) to -$288M (2025), and FCF is -$157M against only $150M cash — the company is structurally dependent on capital markets
- · Serial dilution: January 2025 underwritten offering, February 2026 offering, and an ~$150M raise just diluted holders on the heels of positive data; further raises are explicitly acknowledged as likely before commercialization
- · Single-asset binary risk — the entire ~$1.9B enterprise value hinges on COMP360; any safety signal, CMC issue, or DEA scheduling setback is existential
- · DEA scheduling is a real overhang: psilocybin is Schedule I, and post-approval rescheduling terms (e.g., Schedule II vs. III) will materially influence prescribing friction, site logistics, and commercial ramp
- · Commercialization model is unproven at scale: requires training/certifying third-party clinics for in-clinic administration and monitoring — a delivery bottleneck that could dramatically slow launch even with approval
- · Debt-to-equity of 16.3x and Hercules Capital loan with minimum cash covenants adds financial constraint risk if milestones slip; P/B of 5.77 embeds significant intangible value that erodes quickly on disappointment
Catalysts
- · 26-week COMP006 durability data expected early Q3 2026 — could be a decisive differentiator vs. Spravato
- · Q4 2026 rolling NDA submission for TRD indication
- · H1 2027 potential FDA approval decision
- · Next earnings on 2026-07-30: pipeline updates and cash runway commentary
- · PTSD COMP202 Phase 2b/3 trial initiation following January 2026 IND acceptance
- · Any partnership/collaboration announcement for commercial launch infrastructure or ex-U.S. rights that could offset dilution risk
Key risks
- · Cash runway: $150M cash against ~$160M annual burn implies another dilutive raise is highly likely before an approval decision
- · DEA scheduling outcome post-approval could severely constrain commercial rollout
- · Single-product concentration — any COMP360 setback is existential
- · Executional risk in building an in-clinic administration network from scratch
- · Hercules loan covenants could restrict operations if milestones slip
- · FDA staffing/policy volatility could delay rolling NDA review
What to watch
- · Q3 2026 26-week COMP006 durability readout
- · July 30, 2026 earnings — cash balance, runway commentary, any offering signals
- · FDA meeting outcomes on rolling NDA process and any communication on scheduling review
- · Additional equity offerings or ATM activity (dilution overhang)
- · Hercules Capital milestone/covenant status
- · Technical levels: 52-week high of $15.40 as resistance; support near $10 psychological level
Key metrics
Price target rationale
Base case $18 assumes rolling NDA proceeds on schedule and market applies a modest risk-adjusted peak-sales multiple net of ~15-20% additional dilution before approval. Bull $32 assumes durability data impresses, favorable DEA scheduling signaled, and partnership offsets dilution — approaching analyst mean. Bear $6 reflects an approval delay, restrictive scheduling, or another large dilutive raise pressuring shares back toward mid-52-week range.
On Wall Street's view (mixed): The $23.60 mean target implies ~69% upside and is directionally defensible given derisked Phase 3 data, but the $8–$70 range (nearly 9x spread) reflects genuine uncertainty on scheduling, launch economics, and dilution; we think the base case sits below consensus once further raises are modeled.
Latest filing (10-K)
COMPASS just hit primary endpoints in both Phase 3 TRD trials with p<0.001 and is racing toward a Q4 2026 NDA submission for what could be the first psilocybin treatment approved for a 4-million-patient U.S. market, but it remains pre-revenue, cash-dependent, and faces real DEA scheduling and commercialization execution risks.
COMPASS Pathways plc is a clinical-stage UK-incorporated biotechnology company developing COMP360, a proprietary pharmaceutical-grade psilocybin formulation, for serious mental health conditions. The company has no product revenue and funds operations through equity offerings and debt. Its primary focus is treatment-resistant depression (TRD), with a secondary program in PTSD. It holds global development and commercialization rights to COMP360 and plans a U.S. commercial launch as its first market upon FDA approval.
What the news says · bullish
The dominant storyline is Compass Pathways releasing Phase 3 COMP006 trial data showing psilocybin's depression benefit sustained at 6 months, reinforcing the rolling NDA submission and a potential FDA approval by H1 2027. Analyst reaction is broadly positive — including an Evercore ISI upgrade and a 'Strong Buy' from Seeking Alpha — but the stock's actual price action was mixed to negative on the day, weighed down by an ~$150M equity offering that diluted the trial buzz. The tension between strong clinical/regulatory progress and near-term dilution explains the muted or negative intraday moves despite bullish premarket sentiment. Medium-term catalysts (FDA filing completion, approval timeline) remain intact, but the offering overhang and modest trial data reception relative to high expectations temper the near-term upside.
This analysis is from Jul 9, 2026. Markets move. Get the current read on CMPS and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.